Please Wait
Applying Filters...
menu
    • menu
    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED Finishes Enrollment for SANOVO Phase III Trial in China
    HUTCHMED Finishes Enrollment for SANOVO Phase III Trial in China

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/20/3136084/0/en/HUTCHMED-Completes-Patient-Enrollment-of-SANOVO-Phase-III-Trial-of-ORPATHYS-and-TAGRISSO-Combination-as-a-First-Line-Therapy-for-Certain-Lung-Cancer-Patients-in-China.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Hutchmed Gets China Nod for Orpathys + Tagrisso Combo
    Hutchmed Gets China Nod for Orpathys + Tagrisso Combo

    30 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/30/3107244/0/en/HUTCHMED-Announces-China-Approval-for-ORPATHYS-in-Combination-with-TAGRISSO-for-the-Treatment-of-Lung-Cancer-Patients-with-MET-Amplification-After-Progression-on-First-Line-EGFR-In.html

    GLOBENEWSWIRE
    30 Jun 2025
    Share Share
    Hutchmed Completes Patient Enrollment for Savolitinib Study
    Hutchmed Completes Patient Enrollment for Savolitinib Study

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/22/3065080/0/en/HUTCHMED-Completes-Patient-Enrollment-of-a-Phase-II-Registration-Study-of-Savolitinib-in-Gastric-Cancer-in-China.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    HUTCHMED Highlights Savolitinib SAVANNAH Ph 2 At ELCC 2025
    HUTCHMED Highlights Savolitinib SAVANNAH Ph 2 At ELCC 2025

    19 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3045892/0/en/HUTCHMED-Highlights-Savolitinib-SAVANNAH-Phase-II-and-Other-Data-at-European-Lung-Cancer-Congress-2025.html

    GLOBENEWSWIRE
    19 Mar 2025
    Share Share
    HUTCHMED Gets NMPA Approval For ORPATHYS® In MET Exon 14 NSCLC
    HUTCHMED Gets NMPA Approval For ORPATHYS® In MET Exon 14 NSCLC

    13 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/14/3008991/0/en/HUTCHMED-Announces-NMPA-Full-Approval-for-ORPATHYS-savolitinib-in-China-for-Patients-with-Locally-Advanced-or-Metastatic-MET-Exon-14-NSCLC.html

    GLOBENEWSWIRE
    13 Jan 2025
    Share Share
    Hutchmed's Priority Review For Orpathys-Tagrisso In Lung Cancer
    Hutchmed's Priority Review For Orpathys-Tagrisso In Lung Cancer

    01 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/02/3003295/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-ORPATHYS-and-TAGRISSO-Combination-in-Lung-Cancer-Patients-with-MET-amplification-After-Progression-on-Fir.html

    GLOBENEWSWIRE
    01 Jan 2025
    Share Share